MAM
GILD icon

McLean Asset Management’s Gilead Sciences GILD Stock Holding History

McLean Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
1,768
-44
-2% -$5.8K 0.03% 170
2026
Q1 		$253K Buy
1,812
+15
+0.8% +$2.1K 0.04% 146
2025
Q4 		$223K Buy
1,797
+13
+0.7% +$1.58K 0.04% 162
2025
Q3 		$203K Buy
+1,784
New +$203K 0.04% 167

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McLean Asset Management's GILD Position: Q2 2026 in Review

McLean Asset Management reduced its Gilead Sciences (GILD) stake by 2.4% in Q2 2026, selling an estimated $5.8K and leaving 1,768 shares worth $230K. The position accounts for 0.03% of the portfolio, ranked #170.

McLean Asset Management first reported a position in GILD in Q3 2025 and has held it in 4 quarters since. The position peaked at $253K in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • McLean Asset Management held 1,768 shares of Gilead Sciences worth $230K as of Q2 2026.
  • McLean Asset Management sold 44 Gilead Sciences shares in Q2 2026, an estimated $5.8K.
  • Gilead Sciences made up 0.03% of McLean Asset Management's portfolio in Q2 2026, its #170 holding.
  • McLean Asset Management first reported a position in Gilead Sciences in Q3 2025 and has held it in 4 quarters since.
  • McLean Asset Management's Gilead Sciences position peaked at $253K in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on McLean Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.